References
Armitage J. The safety of statins in clinical practice. Lancet. 2007;370:1781–90.
Iida S, Chou T, Okamoto S, Nagai H, Hatake K, Murakami H, et al. Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma. Int J Hematol. 2010;92:118–26.
Brown JR, Abramson J, Hochberg E, Mikler E, Dalton V, Werner L, et al. A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL. Leukemia. 2010;24:1972–5.
Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Eng J Med. 2007;357:2133–42.
Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Eng J Med. 2007;357:2123–32.
Boga C, Ozdogu H, Yeral M, Kizilkilic E, Tamer L. Thalidomide in combination with dexamethasone-induced rhabdomyolyis in a patient with refractory myeloma. J Support Oncol. 2007;6:256.
van der Spek E, Bloem AC, Lokhorst HM, van Kessel B, Bogers-Boer L, van de Donk NW. Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma. Leuk Res. 2009;33:100–8.
Antons KA, Williams CD, Baker SK, Phillips PS. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med. 2006;119:400–9.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Urata, C., Yoshimura, M., Itamura, H. et al. Lenalidomide in combination with dexamethasone induced rhabdomyolysis in a multiple myeloma patient treated with pravastatin. Int J Hematol 94, 216–217 (2011). https://doi.org/10.1007/s12185-011-0903-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-011-0903-y